

**Figure S1**. Gating strategy to evaluate the CD56<sup>bright</sup> and CD56<sup>dim</sup> NK cell subsets expressing activating or inhibitory markers. NK cells were selected in the lymphocyte region (SSC-A x FSC-A). The CD3<sup>-</sup>CD19<sup>-</sup> population was gated, and then CD56<sup>+</sup> cells were selected to define CD56<sup>bright</sup> (CD56<sup>+</sup>CD16<sup>-</sup>) and CD56<sup>dim</sup> (CD56<sup>+</sup>CD16<sup>+</sup>) NK cells. Each subset was assessed for the expression of NKG2A, NKG2C, NKG2D, CD69, CD127 and CD57.